Menopause:乳腺癌存活者治疗诱导的更年期症状 这种基于互联网的治疗可行

2017-07-24 吴刚 环球医学

2017年7月,发表在《Menopause》的一项初步研究调查了对于乳腺癌存活者治疗诱导的更年期症状,基于互联网的认知行为治疗的可行性。



2017年7月,发表在《Menopause》的一项初步研究调查了对于乳腺癌存活者治疗诱导的更年期症状,基于互联网的认知行为治疗的可行性。

目的:既往研究证实,小组会议中,认知行为治疗(CBT)项目在减轻乳腺癌女性治疗诱导的更年期症状上是有效的,但是,对于一些女性来说,亲自CBT不方便,并能造成较低水平的项目依从性。一种具有前景的替代方法为使用互联网来使这种形式的CBT变得更加可及和可行。本研究的目的为评估可行性,并产生经指导的基于互联网的CBT项目有效性的初步数据。

方法:21名具有治疗诱导的更年期症状的参与者开始经指导的基于互联网的CBT项目。于基线和10周(治疗后)时完成自我报告的调查问卷。指导顾问的评价通过访谈获取。首要结局指标为项目的使用、依从性、参与者和指导顾问的满意度。次要结局指标为内分泌症状的总体水平和潮热/盗汗的发生率。

结果:90%的参与者完成了预期项目。参与者和指导顾问的满意率较高。建议对该项目进行小的修改。内分泌症状的总体水平和潮热/盗汗的发生率随着时间显着减少。

结论:结果表明,对于治疗诱导的更年期症状女性,基于互联网的CBT项目是可行的,并且疗效具有前景。CBT项目的有效性正在一项大型随机对照试验中进行调查。

原始出处:

Atema V, van Leeuwen M, Oldenburg HSA, et al. An Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a pilot study. Menopause. 2017 Jul;24(7):762-767. doi: 10.1097/GME.0000000000000836.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=226440, encodeId=bcf922644097, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Jul 26 09:00:38 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274103, encodeId=dc2712e4103a8, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed Jul 26 03:32:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225854, encodeId=d8072258540d, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jul 24 16:01:55 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225820, encodeId=ddd32258207a, content=谢谢分享,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon Jul 24 13:43:38 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-26 龙胆草

    学习谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=226440, encodeId=bcf922644097, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Jul 26 09:00:38 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274103, encodeId=dc2712e4103a8, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed Jul 26 03:32:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225854, encodeId=d8072258540d, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jul 24 16:01:55 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225820, encodeId=ddd32258207a, content=谢谢分享,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon Jul 24 13:43:38 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=226440, encodeId=bcf922644097, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Jul 26 09:00:38 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274103, encodeId=dc2712e4103a8, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed Jul 26 03:32:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225854, encodeId=d8072258540d, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jul 24 16:01:55 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225820, encodeId=ddd32258207a, content=谢谢分享,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon Jul 24 13:43:38 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-24 137****9095

    henhao

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=226440, encodeId=bcf922644097, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Wed Jul 26 09:00:38 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274103, encodeId=dc2712e4103a8, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Wed Jul 26 03:32:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225854, encodeId=d8072258540d, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Mon Jul 24 16:01:55 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225820, encodeId=ddd32258207a, content=谢谢分享,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKT9Tk01eiaQ9QHMuAiaO48A8OmtM9WGtiatxfLRdPQAmL2UxxjUB0RQDGJjgvWkcaZ8uW38Z4JFq4sw/132, createdBy=f5a62063089, createdName=临风淑玉, createdTime=Mon Jul 24 13:43:38 CST 2017, time=2017-07-24, status=1, ipAttribution=)]
    2017-07-24 临风淑玉

    谢谢分享,学习啦

    0

相关资讯

JAMA:遗传咨询的茫茫前路,BRCA致癌性远比认识复杂

近日,英国剑桥大学科学家的一项研究表明与乳腺癌和卵巢癌相关的早期BRCA突变携带者癌症风险显着增加,BRCA基因突变的位置以及乳腺癌家族史的程度也影响着相关癌症风险的大小。

JCO:曲妥珠单抗联合化疗方案孰优孰劣?

大家都知道化疗和曲妥珠单抗联合治疗已成为表皮生长因子受体2-阳性乳腺癌辅助治疗的标准。有两个方案在美国已得到广泛应用:阿霉素、环磷酰胺、紫杉醇和曲妥珠单抗(ACTH)及多西紫杉醇,卡铂和曲妥珠单抗(TCH)。但是目前这两种方案并没有在临床试验中直接比较,且现有的实验数据对老年患者普遍性有所限制。

Oncologist:乳腺癌CDK4/6抑制剂治疗的潜在副作用都有啥?

细胞周期蛋白依赖性激酶抑制剂的出现已大大改变了激素受体阳性转移性乳腺癌的治疗现状。目前已有多种相关药物,FDA也已批准某些药物可联合内分泌治疗。本文即对相关药物潜在治疗副作用及药物相关作用、及其临床处理进行概述。

JCO: 曲妥珠单抗化疗方案对早期乳腺癌老年妇女的毒性和有效性分析

在老年患者的匹配样本中,与TCH相比,ACTH并没有与严重不良事件或更高住院率相关,但与曲妥珠单抗佐剂的完成负相关。此外,研究人员并没有发现ACTH与TCH在5年存活率上有差异。在老年患者情况有限的背景下,选择这两种方案时如果只是根据毒性差异或治疗效果,可能不合适。

Cell:三阴性乳腺癌细胞可唆使正常细胞模仿病毒帮助肿瘤扩散并耐药

2017年7月13日,美国爱思唯尔旗下《细胞》正式发表宾夕法尼亚大学、罗格斯大学的研究报告稿,发现为何某些乳腺癌比其他乳腺癌更有浸润性、癌细胞如何诱骗正常细胞像病毒一样释放特殊的RNA帮助肿瘤生长、耐药、转移。

JAMA:中青年体重增加可使年老时乳腺癌等疾病风险增加

2017年7月18日,《美国医学会杂志》正式发表哈佛大学陈曾熙公共卫生学院、复旦大学生命科学学院、哈佛大学医学院、布莱根女子医院、美国退伍军人事务部波士顿医疗中心的研究报告,发现从青年(18~21岁)至55岁的体重增加,与生命后期主要慢性疾病和死亡的风险增加、年老时仍保持健康的可能性降低有相关性。